While Romilkimab, which blocks IL-4 and IL-13, has been shown to effectively reduce dermal thickening in systemic sclerosis, it has not been shown to significantly improve lung function, underscoring the challenge of reversing fibrosis once established [101]. The gene discussed is IL13; the disease is systemic sclerosis.